184P A phase I study of the cancer-specific vaccine FMPV-1 in healthy male subjects to assess safety and immune response

Abstract

FMPV-1 is a novel injectable vaccine to generate anti-cancer T cell responses. The vaccine is an immunogenic frameshift mutated transforming growth factor β receptor 2 (TGFβR2) peptide commonly occurring in microsatellite instability cancers (MSI-H). FMPV-1 is administered in combination with the adjuvant granulocyte macrophage colony stimulating factor (GM-CSF). This is the first clinical study to assess the safety and immunogenicity of FMPV-1/GM-CSF in man.